June 3, 2017 Approximately 15% of all patients with non–small cell lung cancer (NSCLC) present with disease in early stages, and yet 5-year survival rates for these individuals never exceed about 54% because of high rates of recurrence following initial treatment. Presenters at the Education Session “Upfront Management of Operable Non–Small Cell Lung Cancer,”…
Pro zobrazení tohoto obsahu je třeba být přihlášen.
 
                    
 
                           
                           
                           
                           
                           
                           
                   
                   
                   
                   
                           
                   
                           
                           
                   
                   
               
                 
                 
                